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ac.in (M.V.N.K. TAbstract A new rapid and sensitive high performance liquid chromatography (HPLC) method has
been developed for the simultaneous determination of atorvastatin—an antihyperlipidemic drug along
with most commonly prescribed drugs (antihyperlipidemic, antihypertensive, antidiabetic, antithrom-
botic) in bulk and marketed combined formulations. The chromatographic separation was carried out
by gradient elution mode with acetonitrile as organic modiﬁer and 0.1% triethylamine acetate (TEAA)
buffer pH 5 at a ﬂow rate of 1 mL/min and a diode array detector at wavelength 230 nm was employed
for detection of the analytes. Calibration curves were linear in the range of 5–150 mg/mL for all the
drugs with correlation coefﬁcients of determination (r2 values)Z0.999. Limits of detection (LODs) and
Limits of quantiﬁcation (LOQs) ranged from 0.1 to 0.27 mg/mL and 0.3 to 0.89 mg/mL respectively.
Intra-day and inter-day precision was studied at three concentration levels (20, 60 and 100 mg/mL). The
intra-day and inter-day RSD for all compounds was less than 2.0%. The accuracy for all compounds
was found to be between 98% and 102%. Thus, the performance of the method described allows its use
in quantiﬁcation of atorvastatin along with 9 most commonly prescribed drugs available in market as
atorvastatin combined dosage forms.
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alluri).1. Introduction
Atheromatous disease is ubiquitous and underlies the commonest
cause of death (myocardial infarction caused by thrombosis) and
disability (stoke, heart failure) in industrial societies. Hyperlipide-
mia and hypertension are the important risk factors for atheroma,
which are amenable to drug therapy. The statins are used in
combination with several different types of cardiovascular drugs to
treat the disease. Atorvastatin [2-(4-ﬂuorophenyl)-b, d-dihydroxy-
5-(1-methylethyl) -3-phenyl-4-[(phenylamino) carbonyl]-1Hpyrrole-
1-heptanoic acid], an antihyperlipidemic drug, is used along with
thrombolytic drugs (aspirin, clopidogrel) in the treatment of
M.V.N.K. Talluri et al.286myocardial infarction. It is also used with antihypertensive
drugs (atenolol, telmisartan, losartan potassium) in the
treatment of hypercholesteremia and in high blood pressure,
with ezetimibe, fenoﬁbrate (anti hyperlipidemic) to treat
hypercholestremia, with antidiabetics (glimeperide, metfor-
min) in the case of diabetes and hypercholestremia [1].
Therefore, atorvastatin is most frequently prescribed in
combined formulations of different drugs.
A thorough literature survey reveals that determination of
atorvastatin alone or in combination with other drugs viz.,
fenoﬁbrate [2–4], ezetimibe [5,6], losartan [7], telmisartan [8],
metformin and glimeperide [9], glimeperide [10], aspirin [11],
clopidogrel and aspirin [12], losartan, aspirin and atenolol [13]
was reported. The afore mentioned analytical methods have
been developed in order to allow quantitative determination of
a maximum of three combinations. In light of the increasing
number of combinations, these separation procedures are
extremely inefﬁcient. It is obvious that a more convergent
methodology is required in order to streamline and simplify
these procedures. We have decided to develop a single methodFigure 1 Chemical structurto identify and quantify atorvastatin with most of the
prescribed combinations available in the market.
Currently the most commonly used analytical method
for determination and quantiﬁcation of drugs is high
performance liquid chromatography which offers greater
versatility and robustness combined with different detec-
tion modes. The introduction of reliable photodiode-array
detectors has dramatically improved the selectivity of
HPLC and afforded a number of advantages previously
attributed only to mass spectrometric detection [14].
Indeed, such a method would be useful for simultaneous
determination of these drugs in different single or com-
pounded formulations, therapeutic drug monitoring and
toxicological screening in forensic samples. Here we report
a rapid and sensitive method for the identiﬁcation and
quantitation of ten drugs (atorvastatin calcium, fenoﬁ-
brate, ezetimibe, atenolol, losartan potassium, telmisartan,
metformin hydrochloride, glimeperide, aspirin, clopidogrel
bisulfate) using gradient reverse phase high-performance
liquid chromatography.es of the studied drugs.
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2.1. Chemicals and reagents
The active pharmaceutical ingredients were obtained as gift
samples from the following local manufacturers: atorvastatin
calcium (ATR), losartan potassium (LSN) and clopidogrel
bisulfate (CLO) from Aurobindo pharma Ltd., aspirin (ASP)
from Accord labs, ezetimibe (EZE) and telmisartan (TSN)
from MSN Laboratories Ltd., metformin hydrochloride
(MET) and glimepiride (GLI) from Dr. Reddy’s Laboratories
Ltd., atenolol (ATE) from Virupaksha Organics Ltd., fenoﬁ-
brate (FEN) from Nivika Chemo-Pharma Ltd., Gujarat,
India. HPLC grade acetonitrile and methanol were obtained
from Merck India. Acetic acid, triﬂuoroacetic acid (TFA) and
triethyl amine (TEA) (AR) were from S.D. Fine Chemicals
Ltd., Mumbai. High purity water was prepared using Milli-Q
gradient ultrapure water system (Billerica, MA 01821, USA).
Triethylamine acetate (TEAA) buffer was prepared by neu-
tralizing a 0.1% solution of triethylamine with glacial acetic
acid until pH 5 was obtained. It was ﬁltered through a 0.45 mm
ﬁlter prior to use. Star pill (Cipla Ltd.), (ATR 10 mg, ATE
50 mg, LSN 50 mg, ASP 75 mg); Telsartan-atr (Dr. Reddy’s
Laboratories Ltd.), (ATR 10 mg, TSN 40 mg); Fibator-ez
(Sun Pharmaceuticals Industries Ltd.), (ATR 10 mg, FEN
160 mg, EZE 10 mg); Deplatt-CV cap (Torrent Pharmaceuti-
cals Ltd.), (ATR 10 mg, ASP 75 mg, CLO 75 mg); Stator
GM2 (Abbott Healthcare pvt.Ltd.), (ATR 10 mg, GLI 2 mg,
MET 500 mg) were purchased from local medical stores.
Fig. 1 shows the chemical structures of the studied drugs.
2.2. Equipment and chromatographic conditions
The HPLC system consisting of two LC-20AD pumps, an
SPD-M 20AUV/VIS detector, a rheodyne injector, an SPD-
M20A diode array detector (PDA), a DGU-20A3 degasser
and a CBM-20A communications bus module (all from
Shimadzu, Kyoto, Japan) was used. The chromatographic
and the integrated data were recorded using LC-solutionTable 1 Chromatographic behavior of the drugs on different co
Sl. no.Buffers pH C18 column
1 0.05%
Triﬂoroacetic
acid (TFA)
4 All drugs are separated, but TSN-bro
Tailing factor (Tf ): MET (1.72), EZE
ATR (1.52), GLI (1.56), FEN (1.56)
2 0.05%
Triﬂoroacetic
acid (TFA)
5 ASP and ATE—overlap
TSN and ATE—poor resolution (Rso
EZE and TEL—less resolution (Rs¼1
Tailing factor (Tf): MET (2.15), LSN
CLO (1.55), FEN (1.56)
3 0.1 %
Triethylamine
acetate (TEAA)
4 ATR and TEL broad peaks,
GLI and EZE—overlap,
Tailing factor (Tf): MET (2.15), LSN
FEN (1.53)
4 0.1 %
Triethylamine
acetate (TEAA)
5 ATR and TSN—less resolution (Rs¼
base to base separation.
Tailing factor (Tf): MET (1.54)data acquiring software. The separation column was a 5 mm
phenyl (250 mm 4.6 mm i.d.) maintained at ambient tem-
perature (27 1C). Elution was performed with gradient elu-
tion of acetonitrile and TEAA mobile phase. The acetonitrile
content of the mobile phase was 5% initially and increased
linearly from 5% to 50% during 5 min and further increased
to 55% from 5 min to 12.5 min and kept constant until
17.5 min and increased to 100% up to 18.5 min. This was
maintained up to 25 min. The mobile phase was used at a
ﬂow rate of 1 mL/min. The UV spectra of individual drugs
were recorded in the wavelength range of 200–400 nm. The
wavelength at 230 nm was considered for the detection of all
drugs with adequate sensitivity. The pH measurements were
carried out with pH meter (Eutech pH Tutor) equipped with
a combined glass–calomel electrode, which was calibrated
using standard buffer solutions of pH 4.0 and 7.0 before
making measurements.
2.3. Preparation of stock and calibration solutions
Stock solutions of ATR, FEN, EZE, ATE, LSN, MET,
ASP, CLO were prepared by dissolving 5 mg of each in
5 mL of methanol. GLI (5 mg) was dissolved in 5 mL of
dioxane and sonicated for 5 min. TSN (5 mg) was dissolved
in 5 mL of methanol and 200 mL of acetic acid added for
enhancing the solubility. Using this stock solutions, serial
dilutions were made to get 8 different concentrations (5, 20,
40, 60, 80, 100, 120, 150 mg/mL) to construct calibration
curve. Responses were measured as peak areas and plotted
against concentration.
2.4. Sample preparation for assay
Twenty tablets of different combinations of atorvastatin were
weighed and grinded. Appropriate amount of powder was
diluted with 10 mL of the diluent, sonicated for 15 min and
ﬁltered through a 0.45 mm whatmann ﬁlter paper, and further
dilutions were made as discussed in Section 3.3.lumns.
Phenyl column
ad peak,
(1.54),
MET retention increased to 4.29
ATR and TSN overlap, GLI—less Rs (1.76)
Tailing factor (Tf) : MET (2.13), LSN (1.68)
MET retention increased to 4.28
1) ATR and TSN, overlap Tailing factor (Tf):
MET (2.1)..6)
(1.57),
MET retention increased to 3.61,
GLI and EZE, overlap TSN and ATR—less
Rs (1.78)(1.52),
1.2)—no MET retention increased to 3.42, minimum
resolution 42.8 and tailing factor (Tf)o1.2 for all
the drugs.
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3.1. Method development and optimization
When methanol and acetonitrile were used in initial scouting,
it was observed that acetonitrile was found to be better in
terms of resolution and peak shapes as compared to methanol.
Therefore, acetonitrile was used as an organic modiﬁer for
method development. We have avoided phosphate buffer as it
is non-volatile and unameanable with an ELSD or a MS
detector. Ammonium acetate buffer (10 mM) was chosen, but
peak shapes and resolutions were found to be unacceptable for
some of the analytes. ATR and TSN were less resolved and
tailing was observed for ASP, EZE and GLI with broader
peaks. The effect of different pH and mobile phase composi-
tion were also tried to improve the resolution and peak
symmetry. The resolution was found to be improved at pH
4 and 5. Two buffers, TFA (acidic) and TEAA (basic) were
chosen to work with different stationary phases for further
improvement in selectivity. In addition to commonly using C18
column, phenyl stationary phase was selected as majority of
the analytes studied are aromatic. It is known that, phenyl
stationary phases are p-basic (electron donating) and interact
by p–p interactions through the phenyl ring with the com-
pound, thereby improving the selectivity. In an attempt to
improve peak symmetry and resolution on C18 column, TFA
(0.05%) was used. But severe tailing was observed for most of
the analytes. In the case of TEAA buffer on C18, ATR and
TSN were less resolved with broader peaks and metformin wasFigure 2 Separation pattern of ATN and its combinations on peluted within 2.5 min. The experiment on phenyl column with
TFA was unsuccessful as ATR and TSN were not fully
resolved and tailing observed (Tf42.0) for MET. In the case
of TEAA at pH 4.0, GLI was not separated from EZE and
resolution between ATR and TSN was also poor. However,
pH 5.0 was found to be suitable to overcome all the difﬁculties
on phenyl column. The phenyl column was found to be more
suitable because of less tailing with improved resolution for all
the drugs and considerable increase in the retention time
(3.5 min) of metformin (polar compound). The resolution was
more than 2.8 min and tailing of less than 1.2 min. Therefore,
phenyl column with TEAA buffer (pH 5) was selected for
further studies. The chromatographic behavior of the all the
drugs on different columns with different buffers is summar-
ized in Table 1. Fig. 2 shows separation pattern of ATR and
its combination drugs on phenyl and C18 columns with both
the buffers at pH 5.
3.1.1. Effect of buffer concentration
Of the various percentages (0.1–0.3%) of TEAA, 0.1% was
found to be highly suitable as the chromatographic peaks of
all the drugs were well separated from each other with
symmetrical peak shapes.
3.1.2. Effect of pH
Further studies were carried out on the pH effect of the buffer
(0.1% TEAA) on elution times, resolution and tailing factors.
The symmetrical peaks were observed at pH 5 with improvedhenyl and C18 columns (detector set at 230 nm, pH 5).
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(Table 1). A typical chromatogram showing the separation of
peaks of 10 drugs is depicted in Fig. 2.3.2. Validation of the method
3.2.1. System suitability
The system suitability was checked by six replicate injections
(100 mg/mL). The system is deemed to be suitable for use as
the tailing factors and resolutions for all the drugs are less
than 1.5 min and greater than 2 min respectively. The chro-
matographic resolution parameters for the drugs are reported
in Table 2.3.2.2. Linearity
The linearity of detector response to different concentrations of
drugs was studied in the range of 5–150 mg/mL at 8 different
concentrations (5, 20, 40, 60, 80, 100, 120, 150 mg/mL). The
samples were analyzed in triplicates at all concentrations.
Calibration curves were constructed and found that correlation
coefﬁcient values of all the studied drugs were observed to be
Z0.999. The regression analysis data for calibration curves
were calculated using the peak areas and the data are shown in
Table 3.Table 2 Chromatographic resolution parameters for the
assayed drugs.
Drug tR Rs N Tf
MET 4.1 – 11,258 1.20
ATE 8.1 26.0 48,313 1.26
ASP 8.5 2.3 53,511 1.04
LSN 10.6 15.1 74,720 1.08
TSN 12.8 10.4 39,690 1.13
ATR 13.6 3.2 55,789 1.03
GLI 15.9 13.4 45,443 1.17
EZE 17.2 3.6 59,358 1.03
CLO 23.8 31.0 462,506 1.20
FEN 24.4 4.3 573,068 1.16
tR¼retention time; Rs¼resolution; N¼number of theoretical
plates; Tf¼ tailing factor.
Table 3 Linearity, LOD, LOQ of the drugs studied.
Drug Range (mg/mL) Regression equation
Metformin 5–150 y¼101810x238772
Atenolol 5–150 y¼22859xþ6874.9
Aspirin 5–150 y¼1863.5x1441
Losartan 5–150 y¼81221x102299
Telmisartan 5–150 y¼131836x82655
Atorvastatin 5–150 y¼43347x23320
Glimeperide 5–150 y¼74923x117337
Ezetimibe 5–150 y¼52750xþ740.27
Clopidogrel 5–150 y¼29253x37989
Fenoﬁbrate 5–150 y¼35423xþ255783.2.3. Limit of detection (LOD) and limit of quantiﬁcation
(LOQ)
The LOD was determined based on signal to noise ratio
using analytical response of three times of the background
noise. The LOQ was determined as the lowest amount of
analyte that was reproducibly quantiﬁed using analytical
response of ten times of the background noise. The data
are shown in Table 3.
3.2.4. Precision
Inter-day variabilities were determined by analysis of standard
solutions at low (20 mg/mL), medium (60 mg/mL) and high
concentration (100 mg/mL) analyzed in triplicate on each of
three consecutive days. The intra-day precision was determined
by a set of ﬁve samples of each concentration on a single day.
The mean value of the concentration and relative standard
deviation (R.S.D) are summarized in Table 4.
3.2.5. Accuracy
Accuracy of the method was determined by investigating the
recovery of each drug at three levels 50 mg/mL, 100 mg/mL, and
150 mg/mL from placebo mixtures (lactose, maize starch, man-
nitol, calcium hydrogen phosphate, magnesium carbonate, gela-
tin, polyvidone microcrystalline cellulose, magnesium stearate,
silicon dioxide, titanium dioxide) spiked with the API solution.
Each concentration was analyzed in triplicate (Table 5).
3.2.6. Robustness
The robustness of the developed method was determined by
analyzing the samples under a variety of conditions of the
method parameters, such as ﬂow rate, pH of the buffer and
buffer concentration. Variation of the pH of the mobile phase
(0.1% TEAA) by 70.2 and the % buffer concentration by
70.05%, ﬂow rate by 70.2 mL/min did not have signiﬁcant
effect on chromatographic resolution in HPLC method.
3.3. Quantitative determination in pharmaceutical
formulations
Twenty tablets each of Stator GM2 Bilayered-tab, Telsartan-atr,
Star pill, Fibator-ez, Deplatt-CV cap were crushed and the
powder equivalent to one tablet weight was weighed and diluted
with dioxane: methanol (3:7, v/v) (or methanol) with 400 mL ofMean coefﬁcient
of correlation
LOD (mg/mL) LOQ (mg/mL)
0.9996 0.15 0.49
0.9994 0.13 0.43
0.9996 0.22 0.72
0.9994 0.25 0.82
0.9991 0.10 0.30
0.9996 0.12 0.40
0.9994 0.27 0.89
0.9994 0.18 0.59
0.9995 0.21 0.69
0.9996 0.23 0.75
Table 4 Inter-day and intra-day precision of drugs.
Drug Concentration (mg/
mL)
Inter-day precision (n¼9) Intra-day (n¼5)
Day 0 (n¼3) Day 1 (n¼3) Day 2 (n¼3) Mean7SD
(mg/mL)
RSD
(%)
Mean7SD
(mg/mL)
RSD
(%)
Mean7SD
(mg/mL)
RSD
(%)
Mean7SD
(mg/mL)
RSD
(%)
Metformin 20 20.170.2 0.7 20.170.1 0.3 20.170.1 0.5 20.170.2 0.7
60 60.170.1 0.2 60.570.3 0.5 60.670.5 0.8 60.770.5 0.8
100 100.470.4 0.4 100.270.1 0.1 100.370.1 0.1 100.270.1 0.1
Atenolol 20 20.170.2 0.7 20.170.1 0.4 20.170.1 0.5 20.170.2 0.7
60 60.270.1 0.2 60.570.3 0.4 60.770.2 0.3 60.970.1 0.2
100 100.370.2 0.1 100.370.2 0.1 100.370.2 0.2 100.470.2 0.1
Aspirin 20 20.370.1 0.6 20.170.1 0.3 20.370.2 0.6 20.370.1 0.6
60 60.270.1 0.2 60.470.2 0.3 60.770.2 0.3 61.070.1 0.2
100 100.270.2 0.2 100.270.1 0.2 100.570.1 0.1 100.470.2 0.2
Losartan potassium 20 20.270.2 0.9 20.270.1 0.4 20.170.1 0.4 20.270.2 0.9
60 60.570.3 0.4 60.570.4 0.7 60.770.2 0.3 60.770.6 0.9
100 100.570.4 0.4 100.370.2 0.2 100.370.2 0.2 100.370.2 0.2
Telmisartan 20 20.370.1 0.3 20.170.6 0.3 20.170.2 0.9 20.370.1 0.3
60 60.770.2 0.3 60.270.2 0.3 60.470.2 0.3 60.770.3 0.5
100 100.370.1 0.1 100.470.2 0.2 100.370.3 0.2 100.470.2 0.2
Atorvastatin
calcium
20 20.370.1 0.5 20.270.3 1.2 20.270.2 0.7 20.370.1 0.5
60 60.470.1 0.2 60.570.2 0.3 60.870.1 0.2 60.770.3 0.4
100 100.270.2 0.2 100.370.2 0.2 100.470.2 0.2 100.470.2 0.1
Glimepiride 20 20.370.1 0.2 20.270.2 0.9 20.370.2 0.6 20.370.1 0.2
60 60.570.1 0.2 60.670.1 0.2 60.670.2 0.3 60.970.1 0.1
100 100.270.2 0.1 100.170.2 0.1 100.370.2 0.1 100.270.2 0.2
Ezetimibe 20 20.270.1 0.5 20.270.2 0.6 20.270.1 0.4 20.270.1 0.5
60 60.470.2 0.3 60.570.3 0.4 60.570.2 0.3 60.970.2 0.3
100 100.270.1 0.1 100.470.2 0.2 100.470.2 0.2 100.370.2 0.2
Clopidogrel
bisulfate
20 20.170.1 0.4 20.370.2 0.6 20.270.1 0.4 20.170.1 0.4
60 60.370.2 0.3 60.570.1 0.2 60.670.2 0.3 60.970.1 0.2
100 100.270.1 0.1 100.270.2 0.1 100.570.1 0.1 100.370.2 0.2
Fenoﬁbrate 20 20.270.1 0.5 20.270.1 0.3 20.270.1 0.3 20.270.1 0.5
60 60.570.2 0.3 60.770.2 0.3 60.770.2 0.3 60.970.1 0.2
100 100.370.1 0.1 100.170.2 0.2 100.370.2 0.2 100.270.1 0.1
Table 5 Extraction recovery of the analytical method, determined by comparing peak area ratios of extracts with those obtained
by direct injection of the same compound.
Drug Recovery placeboþamount
added(50 mg/mL)
Recovery placeboþamount added
(100 mg/mL)
Recovery placeboþamount added
(150 mg/mL)
Recovery (%) RSD (%) Recovery (%) RSD (%) Recovery (%) RSD (%)
Metformin 99.5 1.01 99.1 1.49 99.7 0.56
Atenolol 100.1 0.61 99.4 0.86 99.6 0.62
Aspirin 99.1 1.22 99.2 1.30 99.4 0.89
Losartan 99.0 1.41 99.4 0.76 100.4 0.87
Telmisartan 99.7 0.81 99.3 1.23 99.0 0.51
Atorvastatin 99.6 1.22 99.2 1.28 99.1 1.15
Glimeperide 99.7 1.10 98.6 0.68 99.0 1.12
Ezetimibe 99.3 1.42 98.8 1.12 99.7 0.59
Clopidogrel 98.9 1.24 98.9 1.01 100.1 0.95
Fenoﬁbrate 99.1 1.43 99.0 1.17 99.8 0.74
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Table 6 Quantitative determination in pharmaceutical formulations.
Tablet examined Theoretical amount
(mg/tablet)
Amount found
(mean7SD) (mg)
Recovery (%) RSD (%) (n¼6)
Telsartan-atr ATR-10 mg 10.170.1 101.0 1.5
TSN-40 mg 39.870.4 99.5 1.1
Stator GM2 ATR-10 mg 9.970.1 99.3 1.5
GLI-2 mg 2.070.04 100.5 1.8
MET-500 mg 500.375.0 100.0 1.0
Deplatt-CV cap ATR-10 mg 9.970.1 99.0 1.0
ASP-75 mg 75.070.8 100.0 1.0
CLO-75 mg 75.270.5 100.2 0.9
Fibator-ez ATR-10 mg 10.170.1 101.7 1.1
FEN-160 mg 160.270.8 100.1 0.5
EZE-10 mg 9.970.2 99.8 1.5
Star pill ATR-10 mg 9.970.1 99.4 1.0
ASP-75 mg 75.170.8 100.1 1.0
LSN-50 mg 49.570.5 99.0 1.0
Synchronized separation of atorvastatin and its combined formulations by RP–LC 291acetic acid as an additive (or methanol) respectively and
sonicated for 15 min and further dilutions were made with
mobile phase to obtain concentrations within the linearity range
(50, 20, 10, 50, 50, 75, 75, 40, 64 mg/mL of MET, GLI, ATR,
LSN, ATE, ASP, CLO, TSN, FEN respectively). All the
samples were ﬁltered through whatmann (GD/X 25, polypro-
pylene, 0.45 mm) syringe ﬁlter, before injecting the samples into
the HPLC instrument. The data are shown in Table 6.4. Conclusion
The present method has demonstrated that drugs available
in combinations with atorvastatin can be simultaneously
assayed in bulk and dosage forms using RP-HPLC. The line-
arity of the proposed method was investigated in the range of
5–150 mg/mL. The limits of detection were in the range of 0.1–
0.27 mg/mL and the limits of quantiﬁcation were in the range
of 0.3–0.89 mg/mL for the studied drugs. The method was
found to be linear, accurate, precise and robust. The devel-
oped method was employed for simultaneous determination of
the ten drugs in their combined dosage forms. This method
may ﬁnd wider applications in therapeutic drug monitoring
and in forensic analysis.
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